文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

玛瓦卡姆对症状性梗阻性肥厚型心肌病超声心动图特征的影响

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

EXPLORER-HCM试验的超声心动图分析纳入251例症状性梗阻性肥厚型心肌病患者(玛瓦卡姆组123例,安慰剂组128例),评估30周内关键超声参数变化。玛瓦卡姆组二尖瓣收缩期前向运动完全缓解率80.9% vs 34.0%(P<0.0001),左房容积指数和侧壁E/e'显著改善,且改善与NT-proBNP下降相关。

要点

  • 玛瓦卡姆显著改善症状性oHCM患者二尖瓣收缩期前向运动。
  • 玛瓦卡姆改善左室舒张功能指标如LAVI和侧壁E/e'。
  • LVOT梗阻、LAVI和E/e'改善与NT-proBNP下降相关。

核心结论

  • 玛瓦卡姆显著改善症状性oHCM患者的左室舒张功能及二尖瓣收缩期前向运动。
  • LVOT梗阻、LAVI和E/e'改善与心肌壁应力生物标志物NT-proBNP下降相关。

研究设计与样本

  • EXPLORER-HCM试验的超声心动图核心实验室分析,纳入251例症状性oHCM患者(玛瓦卡姆组123例,安慰剂组128例),评估30周内系列超声参数。

主要发现

  • 玛瓦卡姆组80.9%(76/94)vs 安慰剂组34.0%(33/97)患者30周后二尖瓣收缩期前向运动完全缓解(差异46.8%,P<0.0001)。
  • LAVI平均变化:玛瓦卡姆组-7.5 mL/m2(95%CI -9.0至-6.1)vs 安慰剂组-0.09 mL/m2(95%CI -1.6至1.5),P<0.0001。
  • 侧壁E/e'平均变化:玛瓦卡姆组-3.8(95%CI -4.7至-2.8)vs 安慰剂组0.04(95%CI -0.9至1.0),P<0.0001。
  • 玛瓦卡姆组静息、Valsalva及运动后LVOT压差、LAVI、侧壁E/e'改善与NT-proBNP下降相关(P≤0.03)。
  • LAVI下降与峰值运动氧耗改善相关(P=0.04)。

临床怎么用

  • 玛瓦卡姆可改善oHCM患者超声心动图舒张功能及二尖瓣收缩期前向运动,支持其用于症状性oHCM的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that mavacamten, a cardiac myosin inhibitor, improves symptoms, exercise capacity, and left ventricular outflow tract (LVOT) obstruction in patients with obstructive hypertrophic cardiomyopathy (oHCM). OBJECTIVES: The purpose of this study was to evaluate mavacamten's effect on measures of cardiac structure and function and its association with changes in other clinical measures. METHODS: Key echocardiographic parameters from serial echocardiograms over 30 weeks from 251 symptomatic oHCM patients (mavacamten [n = 123], placebo [n = 128]) were assessed in a core laboratory. RESULTS: More patients on mavacamten (80.9%; n = 76 of 94) vs placebo (34.0%; n = 33 of 97) showed complete resolution of mitral valve systolic anterior motion after 30 weeks (difference, 46.8%; P < 0.0001). Mavacamten also improved measures of diastolic function vs placebo, including left atrial volume index (LAVI) (mean ± SD baseline: 40 ± 12 mL/m2 vs 41 ± 14 mL/m2; mean change from baseline of -7.5 mL/m2 [95% CI: -9.0 to -6.1 mL/m2] vs -0.09 mL/m2 [95% CI: -1.6 to 1.5 mL/m2]; P < 0.0001) and lateral E/e' (baseline, 15 ± 6 vs 15 ± 8; change of -3.8 [95% CI: -4.7 to -2.8] vs 0.04 [95% CI: -0.9 to 1.0]; P < 0.0001). Among mavacamten-treated patients, improvement in resting, Valsalva, and post-exercise LVOT gradients, LAVI, and lateral E/e' was associated with reduction in N-terminal pro-B-type natriuretic peptide (P ≤ 0.03 for all). Reduction in LAVI was associated with improved peak exercise oxygen consumption (P = 0.04). CONCLUSIONS: Mavacamten significantly improved measures of left ventricular diastolic function and systolic anterior motion. Improvement in LVOT obstruction, LAVI, and E/e' was associated with reduction in a biomarker of myocardial wall stress (N-terminal pro-B-type natriuretic peptide). These findings demonstrate improvement in important markers of the pathophysiology of oHCM with mavacamten. (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hegde SM, Lester SJ, Solomon SD, et al. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021. PMID: 34915982. doi:10.1016/j.jacc.2021.09.1381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。